• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SP16 是一种首创的抗炎 LRP1 激动剂,在健康志愿者中进行的 1 期临床试验。

A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.

机构信息

Virginia Commonwealth University School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America.

Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.

出版信息

PLoS One. 2021 May 6;16(5):e0247357. doi: 10.1371/journal.pone.0247357. eCollection 2021.

DOI:10.1371/journal.pone.0247357
PMID:33956804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8101931/
Abstract

BACKGROUND

Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitrypsin.

METHODS

A pilot phase I, first-in-man, randomized, double blind, placebo-controlled safety study was conducted to evaluate a subcutaneous injection at three dose levels of SP16 (0.0125, 0.05, and 0.2 mg/kg [up to 12 mg]) or matching placebo in 3:1 ratio in healthy individuals. Safety monitoring included vital signs, laboratory examinations (including hematology, coagulation, platelet function, chemistry, myocardial toxicity) and electrocardiography (to measure effect on PR, QRS, and QTc).

RESULTS

Treatment with SP16 was not associated with treatment related serious adverse events. SP16 was associated with mild-moderate pain at the time of injection that was significantly higher than placebo on a 0-10 pain scale (6.0+/-1.4 [0.2 mg/kg] versus 1.5+/-2.1 [placebo], P = 0.0088). No differences in vital signs, laboratory examinations and electrocardiography were found in those treated with SP16 versus placebo.

CONCLUSION

A one-time treatment with SP16 for doses up to 0.2 mg/kg or 12 mg was safe in healthy volunteers.

摘要

背景

内源性丝氨酸蛋白酶抑制剂与通过低密度脂蛋白受体相关蛋白 1(LRP1)信号转导介导的抗炎和促生存信号有关。SP16 是一种短肽,模拟α-1 抗胰蛋白酶的 LRP1 结合部分。

方法

进行了一项 I 期、首次人体、随机、双盲、安慰剂对照的安全性研究,以评估三种剂量水平的 SP16(0.0125、0.05 和 0.2mg/kg[最高 12mg])或匹配安慰剂的皮下注射,健康个体中以 3:1 的比例随机分配。安全性监测包括生命体征、实验室检查(包括血液学、凝血、血小板功能、化学、心肌毒性)和心电图(测量对 PR、QRS 和 QTc 的影响)。

结果

SP16 治疗与治疗相关的严重不良事件无关。SP16 与注射时的轻度至中度疼痛相关,与安慰剂相比,疼痛评分在 0-10 疼痛量表上显著更高(6.0+/-1.4[0.2mg/kg]与 1.5+/-2.1[安慰剂],P=0.0088)。与安慰剂相比,接受 SP16 治疗的患者在生命体征、实验室检查和心电图方面没有差异。

结论

单次使用 SP16 治疗剂量高达 0.2mg/kg 或 12mg 在健康志愿者中是安全的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/99bb0df9f5a0/pone.0247357.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/e7e84974ed2a/pone.0247357.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/e51b420a2e3a/pone.0247357.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/935cf6c8dcfc/pone.0247357.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/4e88c80b3a56/pone.0247357.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/99bb0df9f5a0/pone.0247357.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/e7e84974ed2a/pone.0247357.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/e51b420a2e3a/pone.0247357.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/935cf6c8dcfc/pone.0247357.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/4e88c80b3a56/pone.0247357.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb3/8101931/99bb0df9f5a0/pone.0247357.g005.jpg

相似文献

1
A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.SP16 是一种首创的抗炎 LRP1 激动剂,在健康志愿者中进行的 1 期临床试验。
PLoS One. 2021 May 6;16(5):e0247357. doi: 10.1371/journal.pone.0247357. eCollection 2021.
2
α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.α1-抗胰蛋白酶衍生的 SP16 肽在急性和神经性疼痛的啮齿动物模型中表现出疗效。
FASEB J. 2022 Jan;36(1):e22093. doi: 10.1096/fj.202101031RR.
3
Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 - a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein-like Receptor 1- on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction.SP16(一种类似丝氨酸蛋白酶抑制剂的小分子肽激动剂,可激活低密度脂蛋白样受体 1)单次皮下给药治疗 ST 段抬高型心肌梗死患者的急性炎症反应:安全性、耐受性和效果。
J Cardiovasc Pharmacol. 2022 Nov 1;80(5):672-678. doi: 10.1097/FJC.0000000000001331.
4
Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.健康成年人中一种人源化兔单克隆抗体(SSS07)的安全性和耐受性:随机、双盲、安慰剂对照、单次递增剂量试验。
Int Immunopharmacol. 2021 Feb;91:107263. doi: 10.1016/j.intimp.2020.107263. Epub 2020 Dec 28.
5
SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System.丝氨酸蛋白酶抑制剂衍生的小肽(SP16)作为一种潜在的治疗药物,可对抗 HIV 诱导的中枢神经系统细胞中的炎症分子和病毒复制。
Cells. 2023 Feb 15;12(4):632. doi: 10.3390/cells12040632.
6
Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction.低密度脂蛋白受体相关蛋白-1是急性心肌梗死的治疗靶点。
JACC Basic Transl Sci. 2017 Oct 30;2(5):561-574. doi: 10.1016/j.jacbts.2017.05.007. eCollection 2017 Oct.
7
Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.健康成年中国志愿者静脉输注2小时大剂量乌司他丁后的安全性和耐受性:一项随机、双盲、安慰剂对照、剂量递增研究。
PLoS One. 2017 May 11;12(5):e0177425. doi: 10.1371/journal.pone.0177425. eCollection 2017.
8
Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.在健康受试者中单次和多次递增剂量下,达塞曲匹的安全性、耐受性和药代动力学:一项随机、双盲、安慰剂对照、I 期研究。
Clin Drug Investig. 2011;31(5):325-35. doi: 10.1007/BF03256931.
9
A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers.一项I期、安慰剂对照、随机、双盲、单剂量递增范围研究,旨在评估雾化吸入新型生物物理支气管扩张剂(S-1226)在健康志愿者中的安全性和耐受性。
Trials. 2016 Jul 28;17:361. doi: 10.1186/s13063-016-1489-8.
10
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.在健康志愿者和类风湿关节炎患者中评估 sphingosine-1-phosphate receptor-1 选择性激动剂 proximod:一项 1 期、双盲、随机、安慰剂对照、递增剂量试验。
Lancet Rheumatol. 2024 Dec;6(12):e837-e847. doi: 10.1016/S2665-9913(24)00199-1. Epub 2024 Oct 22.

引用本文的文献

1
Assessment of postoperative prognosis in patients with acute ST-segment elevation myocardial infarction after PCI using LRP1.使用LRP1评估急性ST段抬高型心肌梗死患者PCI术后的预后
Front Cardiovasc Med. 2025 Feb 27;12:1520696. doi: 10.3389/fcvm.2025.1520696. eCollection 2025.
2
Low to moderate ethanol exposure reduces astrocyte-induced neuroinflammatory signaling and cognitive decline in presymptomatic APP/PS1 mice.低至中度乙醇暴露可降低 APP/PS1 小鼠亚临床期星形胶质细胞诱导的神经炎症信号和认知下降。
Sci Rep. 2024 Oct 14;14(1):23989. doi: 10.1038/s41598-024-75202-w.
3
Moderate ethanol exposure reduces astrocyte-induced neuroinflammatorysignaling and cognitive decline in presymptomatic APP/PS1 mice.

本文引用的文献

1
Anticoagulant and signaling functions of antithrombin.抗凝血酶的抗凝及信号传导功能
J Thromb Haemost. 2020 Dec;18(12):3142-3153. doi: 10.1111/jth.15052. Epub 2020 Sep 9.
2
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体:免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
3
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
适度乙醇暴露可减少症状前APP/PS1小鼠中星形胶质细胞诱导的神经炎症信号传导和认知衰退。
Res Sq. 2023 Dec 2:rs.3.rs-3627637. doi: 10.21203/rs.3.rs-3627637/v1.
4
SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System.丝氨酸蛋白酶抑制剂衍生的小肽(SP16)作为一种潜在的治疗药物,可对抗 HIV 诱导的中枢神经系统细胞中的炎症分子和病毒复制。
Cells. 2023 Feb 15;12(4):632. doi: 10.3390/cells12040632.
5
Restoration of CD4 T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC.非酒精性脂肪性肝病(NAFLD)期间CD4 T细胞的恢复而不调节肝脏免疫模式不足以预防肝癌。
Cancers (Basel). 2022 Nov 9;14(22):5502. doi: 10.3390/cancers14225502.
6
α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.α1-抗胰蛋白酶衍生的 SP16 肽在急性和神经性疼痛的啮齿动物模型中表现出疗效。
FASEB J. 2022 Jan;36(1):e22093. doi: 10.1096/fj.202101031RR.
抗炎药物在治疗重症新型冠状病毒病 2019(COVID-19)患者中的应用:来自中国临床免疫学家的观点。
Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
4
Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing.低密度脂蛋白受体相关蛋白-1在心脏炎症和梗死愈合中的作用
Front Cardiovasc Med. 2019 Apr 26;6:51. doi: 10.3389/fcvm.2019.00051. eCollection 2019.
5
Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction.将 LRP1 激动剂开发为急性心肌梗死的治疗策略。
Int J Mol Sci. 2019 Jan 28;20(3):544. doi: 10.3390/ijms20030544.
6
Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week.多靶点策略减少心肌缺血/再灌注损伤:美国心脏病学会评论专题的一周。
J Am Coll Cardiol. 2019 Jan 8;73(1):89-99. doi: 10.1016/j.jacc.2018.09.086.
7
Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction.低密度脂蛋白受体相关蛋白-1是急性心肌梗死的治疗靶点。
JACC Basic Transl Sci. 2017 Oct 30;2(5):561-574. doi: 10.1016/j.jacbts.2017.05.007. eCollection 2017 Oct.
8
Inhibiting the Inflammatory Injury After Myocardial Ischemia Reperfusion With Plasma-Derived Alpha-1 Antitrypsin: A Post Hoc Analysis of the VCU-α1RT Study.用血浆源性α-1抗胰蛋白酶抑制心肌缺血再灌注后的炎症损伤:VCU-α1RT研究的事后分析
J Cardiovasc Pharmacol. 2018 Jun;71(6):375-379. doi: 10.1097/FJC.0000000000000583.
9
A Preclinical Translational Study of the Cardioprotective Effects of Plasma-Derived Alpha-1 Anti-trypsin in Acute Myocardial Infarction.血浆源性α-1抗胰蛋白酶在急性心肌梗死中心脏保护作用的临床前转化研究
J Cardiovasc Pharmacol. 2017 May;69(5):273-278. doi: 10.1097/FJC.0000000000000474.
10
Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia-Reperfusion Independent of Elastase Inhibition.重组人α-1抗胰蛋白酶-Fc融合蛋白可减轻小鼠缺血再灌注后的心肌炎性损伤,且与弹性蛋白酶抑制无关。
J Cardiovasc Pharmacol. 2016 Jul;68(1):27-32. doi: 10.1097/FJC.0000000000000383.